Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma

1 clinical trials · Condition

Record	Firm	Date
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) (NCT02955069)	Novartis Pharmaceuticals	2017-02-14

Every clearance here is in the API, with alerts when new ones post.